Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study

Phase 4 Completed 200 enrolled Yamaguchi University Hospital Iwate Medical University · collab Nakamura Memorial Hospital · collab Ootemachi Hospital · collab Tohoku University · collab

RandomizedParallel-groupOpen-labelPrevention

Summary

Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most common cause of morbidity and mortality. Recent studies indicate that Rho-kinase play an important role in the occurrence of such cerebral vasospasm. Eicosapentaenoic acid (EPA) inhibits sphingosylphosphorylcholine (SPC)-induced Rho-kinase activation in vitro. So this study examines whether EPA prevents cerebral vasospasm occurrence after SAH in patients.

Timeline

Start: 2004-12
Primary completion: 2008-06
Completion: 2008-12

Outcome

Met primary endpoint

paper The occurrences of SV (15% vs. 30%; P = 0.022) and CIV (7% vs. 21%; P = 0.012) were lower in the EPA group. PMID 23032083 ↗

Publications

Yoneda H, Shirao S, Nakagawara J, Ogasawara K, Tominaga T, Suzuki M. A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study. World Neurosurg. 2014 Feb;81(2):309-15. doi: 10.1016/j.wneu.2012.09.020. Epub 2012 Sep 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	icosapent ethyl	Small molecule	900 mg	Oral